The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure
- PMID: 19372795
- DOI: 10.1097/01.COH.0000209582.82328.b8
The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure
Abstract
Purpose of review: Despite remarkable progress in the development of drugs that inhibit HIV-1 replication, eradication of the infection has not been achieved. The principal reason is that the virus can persist in stable cellular reservoirs, the best characterized of which is a small pool of latently infected resting memory CD4 T cells that carry a stably integrated viral genome. This review covers recent discoveries on the biology of this reservoir, particularly as related to efforts to eliminate it.
Recent findings: New studies suggest how the reservoir may be established during acute infection and define where the virus integrates in the human genome. In addition, the relationship between the latent reservoir and the residual low-level virus production that continues even in patients on optimal therapy is becoming clear. Several recent studies have described approaches for eliminating the latent reservoir. New insights into the biology of the reservoir are providing a context for understanding the enormous obstacles that must be overcome before the reservoir can be eliminated.
Summary: The latent reservoir presents a formidable therapeutic challenge because it allows the virus to persist as genetic information in the form of a stably integrated provirus in an inherently stable cellular compartment. Eradication is complicated by the fact that the virus can undergo exponential expansion once drug pressure is released. Thus eradication must be complete to be effective.
Similar articles
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
-
The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials.Curr Opin HIV AIDS. 2006 Jan;1(1):62-8. doi: 10.1097/01.COH.0000191897.78309.70. Curr Opin HIV AIDS. 2006. PMID: 19372786
-
Establishment of latent HIV-1 infection of resting CD4(+) T lymphocytes does not require inactivation of Vpr.Virology. 2000 Dec 5;278(1):227-33. doi: 10.1006/viro.2000.0650. Virology. 2000. PMID: 11112497
-
The challenge of viral reservoirs in HIV-1 infection.Annu Rev Med. 2002;53:557-93. doi: 10.1146/annurev.med.53.082901.104024. Annu Rev Med. 2002. PMID: 11818490 Review.
-
Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution.Top HIV Med. 2005 Aug-Sep;13(3):96-100. Top HIV Med. 2005. PMID: 16170226
Cited by
-
Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch.Retrovirology. 2015 Oct 6;12:85. doi: 10.1186/s12977-015-0211-3. Retrovirology. 2015. PMID: 26438393 Free PMC article.
-
Genetic Consequences of Antiviral Therapy on HIV-1.Comput Math Methods Med. 2015;2015:395826. doi: 10.1155/2015/395826. Epub 2015 Jun 10. Comput Math Methods Med. 2015. PMID: 26170895 Free PMC article. Review.
-
Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction.J Neurovirol. 2007 Jun;13(3):210-24. doi: 10.1080/13550280701327038. J Neurovirol. 2007. PMID: 17613711
-
Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART® Molecules.Front Immunol. 2021 Aug 13;12:710273. doi: 10.3389/fimmu.2021.710273. eCollection 2021. Front Immunol. 2021. PMID: 34484212 Free PMC article.
-
HIV Eradication Strategies: Implications for the Central Nervous System.Curr HIV/AIDS Rep. 2019 Feb;16(1):96-104. doi: 10.1007/s11904-019-00428-7. Curr HIV/AIDS Rep. 2019. PMID: 30734905 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Research Materials